A Phase 1 Open-label, Multicenter, Randomized, 2-period, Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects
Latest Information Update: 13 May 2020
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 11 May 2020 Status changed from active, no longer recruiting to completed.
- 16 Oct 2018 Planned End Date changed from 6 Jan 2019 to 9 Dec 2018.
- 28 Jun 2018 Planned End Date changed from 19 Mar 2019 to 6 Jan 2019.